AMLX (Amylyx Pharmaceuticals) Margin of Safety % (DCF FCF Based): N/A (As of Jun. 25, 2026)


AMLX Amylyx Pharmaceuticals Inc AMLX
33 GF Score
Price $17.44
! 2 Warning Signs
View Full Analysis

What is Amylyx Pharmaceuticals Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Amylyx Pharmaceuticals's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

AMLX vs PRGO, ANIP, HROW: Margin of Safety % (DCF FCF Based) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Amylyx Pharmaceuticals's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Amylyx Pharmaceuticals Margin of Safety % (DCF FCF Based) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amylyx Pharmaceuticals's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Amylyx Pharmaceuticals's Margin of Safety % (DCF FCF Based) falls into.


AMLX
33GF Score
Amylyx Pharmaceuticals Inc AMLX
Margin of Safety % (DCF FCF Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Amylyx Pharmaceuticals Business Description

Address 55 Cambridge Parkway, Suite 6W, Cambridge, MA, USA, 02142
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.
33GF Score

Get the complete analysis for AMLX

Margin of Safety % (DCF FCF Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$17.44
Price